Exit this survey

1. Speaker Survey

Please rank each nominee in order of your desire to see them come speak as the 2011-2012 Roseman Lecturer, on a range from "not interested" meaning you have no particular interest in this speaker to "very interested," meaning you are very excited about the possibility of seeing this speaker. Note that as there are five nominees and five interest levels, please only use each interest level once.

Please note: You can click on the name of the researcher to explore their research page for additional information. Clicking on the "Author Report" Hyperlink will route you to the ISI Web of Knowledge where it lists the nominee's most cited work and other relevant information. This link may take a few seconds to load.

Voting will close Friday, September 7th.

For additional concerns or comments please email jhu.chem.slc@gmail.com

Question Title

1. Stephen L. Buchwald - Massachusetts Institute of Technology
The research in the Buchwald group combines elements of organic synthesis, physical organic chemistry and organometallic chemistry to devise catalytic processes of use in solving problems of fundamental importance. In this way the Buchwald group invents or develops new techniques, determines how they proceed and applies them in synthetically interesting contexts. The Buchwald group develops new ligands; utilizes continuous flow chemistry using microreactors and capillary tubing; and develops methods for the formation of carbon-carbon, carbon-nitrogen, and carbon-fluorine bonds.

ISI Web of Knowledge Author Report

Question Title

2. Eric N. Jacobsen - Harvard University
Jacobsen's research focuses on the development of new catalysts for organic synthesis, with an emphasis on asymmetric catalysis. His laboratory has developed useful asymmetric catalysts for alkene epoxidation, epoxide resolution, imine addition, and cycloaddition reactions. These studies identified two broadly useful catalyst scaffolds (the salen-ligated metal complexes and thiourea organocatalysts) that have had a large impact on the field of asymmetric catalysis. The development of synthetic methods is accompanied by their application to problems in complex molecule synthesis, and studies of mechanism and stereoinduction.

ISI Web of Knowledge Author Report

Question Title

3. William R. Roush - The Scripps Research Institute
Dr. Roush's research centers on total synthesis, reaction development, and medicinal chemistry of stereochemically complex, biologically active natural products. Of particular interest is the use of intramolecular and transannular Diels-Alder reactions to explore the intrinsic reactivity of putative Diels-Alderase enzymes. The total syntheses and methods development are directed towards medicinally relevant compounds. Current targets include chemotherapeutics that exploit tumor cell metabolism, antiparasitic agents that inhibit cysteine proteases, and diagnostic probes.

ISI Web of Knowledge Author Report

Question Title

4. Timothy M. Swager - Massachusetts Institute of Technology
The Swager group's research is broadly focused on supramolecular and materials chemistry. The Swager group investigates a spectrum of topics with an emphasis on the synthesis and construction of functional assemblies. Molecular recognition pervades a great deal of their research. Chemosensors require recognition elements to discriminate chemical signals. Electronic polymers are one of the areas that the Swager group is well known for having made many innovations. The Swager group researches a broad range of topics including synthetic chemistry, organic chemistry, polymer chemistry, inorganic chemistry, organometallic chemistry, electro-chemistry, photo-chemistry, and liquid crystal science.

ISI Web of Knowledge Author Report

Question Title

5. Christopher Walsh - Harvard Medical School
The Walsh group researches the molecular bases of biological catalysis with a focus on the structure and function of enzymes. The current focus of the group is on the biosynthesis and mechanism of action of antibiotics and siderophores. Christopher Walsh has pioneered the research and understanding of the widely prescribed late stage antibiotic vancomycin. Vancomycin is a front line antibiotic for the treatment of life-threatening gram positive bacterial infections. Recently however, many clinical isolated have become resistant to the drug and in response the Walsh group has focused interest in successors to vancomycin. Other research projects include Microcin B17, bacterial siderophore biogenesis, macrocylcization of nonribosomal peptides and hydrid poly-ketide synthases (PKS) and non-ribosomal peptide synthestase (NRPS).

ISI Web of Knowledge Author Report

Question Title

6. If you are interested in helping with the organization and/or planning of this event please leave your email below.

T